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A B S T R A C T
Purpose
Despite current treatment after transurethral resection of a bladder tumor, recurrences and
progression remain a problem. Keyhole limpet hemocyanin (KLH) was beneficial in earlier studies.
In this study, safety and efficacy of KLH were compared with that of mitomycin (MM).
Patients and Methods
Patients with intermediate- and high-risk non–muscle-invasive bladder cancer (NMIBC) without carcinoma
in situ were enrolled in a randomized phase III trial. In all, 283 patients were randomly assigned for 16
adjuvant intravesical instillationswith KLH after preimmunization, and 270 patientswere randomly assigned
for 11 adjuvant intravesical instillations with MM. Primary outcome measurement was recurrence-free
survival (RFS). Secondary outcome measurements were progression-free survival, adverse events (AEs),
and the effect of delayed-type hypersensitivity (DTH) response on clinical outcome.
Results
There were significantly more pT1 tumors in the MM group (P  .01). In a log-rank test, univariate
and multivariate Cox regression analysis, KLH was less effective than MM regarding RFS (all P 
.001). Progression was uncommon (n  20). In univariate Cox regression analyses, KLH tended to
prevent progression more effectively than MM, but in multivariate Cox regression analyses, this
could not be shown. AEs were common but mild. Fever, flu-like symptoms, and fatigue occurred
significantly more after KLH treatment. Allergic reactions and other skin disorders occurred
significantly more after MM treatment. Significantly more DTH-positive patients developed a
recurrence than DTH-negative patients.
Conclusion
KLH had a different safety profile and was inferior to MM in preventing NMIBC recurrences. KLH
tended to be more effective than MM in preventing progression. More research is needed to
clarify the immunologic effects of KLH and the effects of KLH on progression.
J Clin Oncol 30:2273-2279. © 2012 by American Society of Clinical Oncology
INTRODUCTION
Worldwide, about 386,300 new cases and 150,200
deaths from bladder urothelial cell carcinoma oc-
curred in 2008.1 Approximately 70% is non–
muscle-invasive bladder cancer (NMIBC).2 The
risk of recurrence and progression after treatment
varies. Low-grade Ta NMIBC has a high chance of
recurrence and a low chance of progression,
whereas high-grade tumors have a high potential
for malignancy. Treatment consists of transure-
thral resection of the bladder tumor (TURBT),
followed by intravesical treatment. The choice of
adjuvant treatment with either chemotherapy (eg,
mitomycin [MM]) or immunotherapy (eg, Bacil-
lus Calmette-Gue´rin [BCG]) depends on the risk
group to which the patient belongs.3-6 Unfortu-
nately, recurrences and adverse events (AEs)
are common.7
Keyhole limpet hemocyanin (KLH), a glyco-
protein from the gastropod mollusk Megathura
crenulata is an immunocyanin that contributes to
the uptake, transport, and release of oxygen during
respiration. It also activates both the humoral and
cellular immune systems, but the precise mecha-
nism of action of KLH remains unknown.8 One
commercially available intravesical immunocyanin
is Immucothel (biosyn, Fellbach, Germany).
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Olsson et al9 were the first to report on KLH in 1974, with
promising results on tumor recurrence. Results of other small phase II
studies suggested a potential benefit of KLH over known treatments
and a favorable safety profile.10-12 Our goal was to compare the efficacy
and safety of KLH with that of MM in a prospective, randomized
phase III trial.
PATIENTS AND METHODS
Eighteen Dutch institutions participated in this multicenter, prospective, ran-
domized phase III trial. The study was conducted in compliance with Good
Clinical Practice, the Declaration of Helsinki (version 1996), and with permis-
sion of all local ethical committees.
Patient Selection
Patients with a histologically proven pTa/1 grade 2 to 3 tumor, or with
multiple or recurrent pTa grade 1 tumors, in whom complete TURBT was
possible, were included after obtaining informed consent. Patients who re-
ceived intravesical therapy within 6 months before entry or more than one
instillation of MM within 2 years before inclusion were excluded. Patients with
primary solitary pTa grade 1 tumors, carcinoma in situ (CIS), or tumors 
pT2 were also excluded. Other exclusion criteria were concurrent malignancy
(except basal cell or squamous cell carcinoma of the skin), history of another
malignancy with a disease-free interval 5 years, expected poor compliance,
WHO performance status more than 2, uncontrollable urinary tract infection,
any previous systemic cancer therapy or radiotherapy within 5 years, localiza-
tion of tumor in prostatic urethra or upper urinary tract, pregnancy or lacta-
tion for women of reproductive age who refused to take adequate
contraceptive measures, congenital or acquired immune deficiency syn-
dromes, known hypersensitivity to MM, and previous (1 month) or current
treatment with an investigational drug.
Treatment Schedule
After TURBT was complete and informed consent was signed, patients
were randomly assigned for treatment with either KLH (Immucothel) or MM.
The restricted blockwise procedure was used for random assignment.
In the KLH arm, patients started with preimmunization: intracutaneous
(IC) injection of 1 mg KLH at intervals of 2 to 7 days until a delayed-type
hypersensitivity (DTH) response was obtained. A real DTH response was
defined as a palpable infiltrate in the skin. In case no DTH response developed,
up to four IC injections were given. Intravesical treatment was started within 2
weeks after the TURBT, independent of the preimmunization result. If there
was no DTH response after four injections, this was not a reason for discon-
tinuing the treatment. Patients received a total of 16 intravesical instillations
(20 mg KLH in 20 mL solvent) given once per week for 6 weeks and then once
per month for 10 months (months 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12).
In the MM arm, patients received a total of 11 instillations (40 mg MM in
50 mg saline) given once per week for 4 weeks (weeks 1, 2, 3, and 4) and once
per month for 5 months (months 2, 3, 4, 5, and 6) and then at 9 and 12 months.
Follow-Up and Evaluation of Therapy
Patients received urinary cytology and cystoscopy every 3 months for the
first year, every 4 months during the second and third years, and every 6
months thereafter. All visible lesions were completely resected and confirmed
by histologic examination. If a recurrence without progression was observed
during the treatment period, the therapy was continued after complete
TURBT. Patients went off-study in case of withdrawal of informed consent,
second recurrence during treatment, first recurrence after completion of ther-
apy, 5-year disease-free survival, occurrence of CIS, tumor of upper tract or
prostatic urethra, or distant metastasis. Patients in whom a lesion was coagu-
lated, not biopsied, or not treated at all continued in follow-up and were
censored at the time of last follow-up.
Objectives and Statistical Analysis
The primary end point was the duration of recurrence-free survival
(RFS). Secondary objectives were recurrence rate, number of recurrent tu-
mors, duration of progression-free survival (PFS), AEs, and the effect of DTH
response on clinical outcome. RFS was defined as the time interval between
TURBT and time to first recurrence. Recurrence was defined as positive
cystoscopy and histologically confirmed positive biopsies. Recurrence rate was
defined as the number of cystoscopies at which recurrences were observed
divided by the duration of follow-up in months multiplied by 100. PFS was
defined as the time interval between TURBT and time to progression. Progres-
sion was defined as recurrence with histologic pathology stage pT2, distant
metastases, or death related to bladder cancer.
KLH is registered for prevention of bladder cancer after TURBT and after
failure of established therapies. Therefore, a subgroup analysis was done in
which RFS after KLH treatment was compared with MM treatment in patients
with recurrence disease and a history of intravesical treatments.
Power analysis showed that 251 evaluable patients were needed in each
treatment group to reject the hypothesis of noninferiority, at error rates of
/2 .025 and .20. With an expected dropout rate of 10%, a total of 552
patients were needed in this study. The study was designed as a noninferiority
study regarding RFS. Inferiority was defined as a ratio of median RFS (tKLH/
tMM) more than 0.75 (eg, 1.31/1.75 years), assuming proportional hazards.
The Kaplan-Meier method and one-sided log-rank test were used to
compare for differences in RFS and PFS between the two treatments. Crude
hazard ratios (HRs) with univariate Cox regression were used to analyze the
influence of patient and tumor characteristics separately on RFS and PFS.
Adjusted HRs with multivariate Cox regression were used to correct for con-
founding factors. Patient and tumor characteristics were compared by using a
two-sided 2 test. Number of patients with a recurrence was compared by
using a one-sided Fisher’s exact test. Number of recurrent tumors was com-
pared by using the one-sided Mann-Whitney U test, and toxicity was com-
pared by using the two-sided 2 test. Effect of DTH response on outcome was
analyzed with two-sided2 tests and log-rank tests. All two-sided analyses were
performed at a 5% level of significance; all one-sided analyses were performed
at a 2.5% level of significance. Statistical analyses were done with SPSS version
16.0 software (SPSS, Chicago, IL).
RESULTS
Between July 2003 and November 2007, 553 patients were ran-
domly assigned: 283 patients to treatment with KLH and 270 to
treatment with MM. For safety analysis, 537 patients were avail-
able: 273 patients in the KLH group and 264 patients in the MM
group. A total of 272 patients received at least one KLH instillation,
and 263 patients received at least one MM instillation. One patient
was randomly assigned for KLH but received MM and was in-
cluded in the MM group. One patient did not receive KLH treat-
ment but experienced an AE before instillation, so he was included
in the KLH group (Fig 1).
For the efficacy analyses, 267 patients in the KLH arm and 256
patients in the MM arm were included. In the KLH arm, 16 patients
were excluded: 10 did not receive any instillation, one patient was
treated with MM, and five patients were ineligible (concurrent malig-
nancy, n3; incomplete TURBT, n2). In the MM arm, 14 patients
were excluded: seven did not receive any instillation, and seven were
ineligible (concurrent malignancy, n 6; tumor in prostatic urethra,
n 1; Fig 1).
Patient and Tumor Characteristics
Patient and tumor characteristics were comparable in both effi-
cacy groups (Table 1), with the exception of tumor stage. Patients in
the MM group had significantly more pT1 tumors (two-sided 2 test
P .015) but not significantly more grade 3 tumors (two-sided2 test
P  .235). DTH response was positive in 61.8% of patients treated
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with KLH (165 of 267), negative in 97 patients (36.3%), and unknown
in five patients (1.9%).
Safety
AEs were common (72% of all patients) but generally mild
(56%), with no differences between the KLH and MM arms (557 AEs
v 514 AEs). No differences in frequency of AEs grouped in system
classes were found except for two AE system classes. General disorders
such as fever, flu-like symptoms, and fatigue occurred significantly
more frequently in the KLH group (51 AEs v 28 AEs; two-sided2 test
P .02). Allergic reactions and skin disorders such as eczema, rash,
and itch occurred significantly more frequently in the MM group (53
AEs v 9 AEs; two-sided 2 test P .001). Significantly more mild AEs
occurred in patients with a positive DTH response (two-sided 2 test
P .004; Table 2).
Efficacy
In total, 163 patients (61%) developed a recurrence after KLH
instillations compared with 87 (34%) after MM instillations (one-
sided Fisher’s exact testP .001). Median RFS in the KLH group was
significantly shorter than that in the MM group (106 weeks [95% CI,
86 to 126 weeks] v297 weeks [95% CI, 202 to 392 weeks]; log-rank test
P .001; Fig 2). Some recurrences occurred outside the bladder: three
recurrences in the MM group (once in the prostatic urethra; twice in
the upper urinary tract) and four in the KLH group (all in the pros-
tatic urethra).
Univariate Cox regression for RFS showed a crude HR of 2.26 for
KLH (95% CI, 1.74 to 2.94; P  .001; Table 3). Multivariate Cox
regression showed an adjusted HR of 2.32 for KLH (95% CI, 1.79 to
3.02; P .001). Ratio of median RFS was 106 of 297 or 0.36 (95% CI,
0.321 to 0.426). Because 0.426 is far below the threshold of 0.75, KLH
is inferior to MM regarding RFS at a 0.001 level of significance.
Significantly more patients developed progression after MM
(n  15) than after KLH (n  5; one-sided Fisher’s exact test;
P .015). Univariate analyses showed a possible relationship between
treatment and progression chances in favor of KLH (log-rank test
P .049; univariate Cox regression HR, 0.38 [95% CI, 0.14 to 1.04];
P  .059; Table 3). In the multivariate Cox regression analysis, this
relationship was less obvious (adjusted HR, 0.43 [95% CI, 0.15 to
1.17]; P .099; Table 4).
Assessed 
(N = 553)
Random allocation
Enrollment
Allocation
Follow-Up
Analysis
Excluded
Allocated to KLH
Received allocated 
   intervention
Did not receive allocated 
   intervention
      Allocated to KLH but 
         received MM
      Consent withdrawn
      Ineligible
(n = 283)
(n = 272)
(n = 11)
(n = 1)
(n = 2)
(n = 8)
Allocated to MM
Received allocated 
   intervention
Did not receive allocated 
   intervention; ineligible
(n = 270)
(n = 263)
(n = 7)
Lost to follow-up
Reason: unknown
Discontinued intervention
   Second recurrence during 
      treatment
   Administrative error
   Adverse events
   CIS recurrence 
   First recurrence during 
      treatment
(n = 1)
 
(n = 103)
(n = 45)
(n = 13)
(n = 11)
(n = 11)
(n = 11)
(n = 0)
Lost to follow-up
Reason: unknown
Discontinued intervention
   Adverse events
   Administrative error
   Consent withdrawn
   Progression 
  
(n = 0)
 
(n = 61)
(n = 30)
(n = 7)
(n = 6)
(n = 6)
Safety analysis (n = 273): received at
least one instillation (n = 272) + patient
with AE prior to treatment (n = 1)
Efficacy analysis (n = 267): 283 – no
treatment received (n = 10) – treated
with MM (n = 1) – ineligible (n = 5)
Safety analysis (n = 264): received at
least one instillation (n = 263) +
patient was randomized for KLH but
received MM (n = 1)
Efficacy analysis (n = 256): 270 – no
treatment received (n = 7) – ineligible
(n = 7)
Fig 1. CONSORT diagram. AE, adverse
event; CIS, carcinoma in situ; KLH, key-
hole limpet hemocyanin; MM, mitomycin.
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The mean number of recurrent tumors after KLH was 3.1 (stan-
dard deviation, 3.1) and 2.4 after MM (standard deviation, 2.2; one-
sided Mann-Whitney U test P .154). Recurrence rate was 2.32 after
KLH and 1.05 after MM. Significantly more DTH-positive patients
than DTH-negative patients developed a recurrence (two-sided 2
test P  .031; Table 5), but RFS and number of recurrences were
not significantly different (log-rank test P  .163 and two-sided t
test P  .108, respectively). Significantly more patients with a
negative DTH response (n  4) than DTH-positive patients
(n 1) showed progression (two-sided 2 test P .044), and time
to progression tended to be shorter for DTH-negative patients
(log-rank test P .051).
For the subgroup analysis in patients with recurrent disease and a
history of intravesical treatments, a total of 81 patients were identified
(49 in the KLH group and 32 in the MM group). The number of
patients with recurrences and time to recurrence was not statistically
significantly different for the two treatment groups (one-sided Fisher’s
exact test P .194 and log-rank test P .558, respectively).
DISCUSSION
In this prospective, randomized phase III trial, significantly more
recurrences occurred after treatment with KLH compared with
MM (P  .001). Literature reporting on KLH and recurrence
chances is diverse, and the number of patients is low. Jurincic et al10
treated 44 patients with either KLH (single IC preimmunization
followed by an unknown number of monthly instillations with 10
mg KLH) or MM (unknown number of monthly instillations with
20 mg MM in 30 mL saline) and found significantly fewer recur-
rences after KLH treatment than after MM treatment (P  .05).
Ka¨lble et al11 compared KLH (IC preimmunization followed by
instillations [10 mg KLH in 20 mL saline] given once per week for
Table 1. Patient Demographics and Clinical Characteristics at Study Entry for All Patients in the Efficacy Analyses
Characteristic
KLH MM Total
PNo. % SD No. % SD No. % SD
No. of patients 267 256 523
Sex .910
Male 218 210 428
Female 49 46 95
Mean age, years 66.9 10.3 67.7 9.3 67.3 9.8 .428
History of CIS 3 4 7 .502
Tumor status .476
Primary 144 54 146 57 290 55
Recurrent 123 46 110 43 233 45
Previous treatment in patients with recurrent tumors at
baseline (n  233) .086
Current single-post TURBT intravesical chemotherapy 5 4 2 2 7 3
Previous single-post TURBT intravesical chemotherapy 10 8 3 3 13 6
Local adjuvant intravesical therapy 31 25 27 25 58 25
Other therapy 3 2 0 0 3 1
No therapy other than TURBT 74 60 78 71 152 65
Tumor stage .015
pTa 216 81 184 72 400 76
pT1 51 19 72 28 123 24
Tumor grade .235
1 88 33 79 31 167 32
2 148 55 134 52 282 54
3 31 12 43 17 74 14
No. of tumors .849
Single 89 33 83 32 172 33
Multiple 178 66 172 67 350 67
Unknown 0 1 0 1 0
Largest diameter, mm 20 29 19 16 39 24 .496
NOTE. Patients in the mitomycin (MM) group had significantly more pT1 tumors than patients in the keyhole limpet hemocyanin (KLH) group (two-sided 2 test
P  .015).
Abbreviations: CIS, carcinoma in situ; SD, standard deviation; TURBT, transurethral resection of bladder tumor.
Table 2. Severity and Number of Adverse Events Per DTH Response
Severity
DTH Response
Total
Positive Negative Unknown
No. % No. % No. %
Mild 207 64 111 50 1 12.5 319
Moderate 96 30 89 39 6 75 189
Severe 22 7 25 11 1 12.5 48
Unknown 0 0 1 0 0 0 1
Total 325 224 8 557
NOTE. Patients with a positive delayed-type hypersensitivity (DTH) response
had significantly more adverse events (two-sided 2 test P  .004).
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6 weeks, once per month for the next 4 months, followed by two
more instillations given at months 7 and 10) to BCG (instillations
[120 mg BCG in 50 mL saline] given once per week for 6 weeks,
once per month for the next 4 months, followed by two more
instillations at months 7 and 10) in 38 patients and reported more
recurrences after treatment with KLH (41.2% v 14.3% after BCG
instillations). Jurincic-Winkler et al13 found that 11 (52%) of 21
patients with CIS achieved a complete response after preimmuni-
zation and instillation with 20 mg KLH in 20 mg saline once per
week for 2 weeks, of which five patients (24%) remained CIS free
during follow-up (mean follow-up, 31.7 months). The long-term
outcome showed long-term tumor remission in only two pa-
tients.14 Echarti et al15 found a significantly longer RFS in 37
patients after KLH treatment compared with several other intra-
vesical treatments (P  .0012). However, treatment schedule and
KLH dosage varied among these patients. Lamm et al6 treated 64
patients with CIS and/or residual tumor with KLH (IC preimmu-
nization followed by instillations once per week for 6 weeks with
KLH in increasing dosages: 0.4, 2.0, 10, and 50 mg). Complete
response was seen in 50% of patients with CIS and in 20% of
patients with residual tumor. Linn et al16 reviewed KLH efficacy
and concluded that it appeared to be similar or better than intra-
vesical chemotherapy. However, best dosage, treatment interval,
and manner of application (intravesical, intralesional, or systemic)
remains uncertain. In all, studies on KLH are small with a wide
variety of inclusion criteria and treatment schedules and therefore
diverse results.
In our study, progression was uncommon (3.8%; n  20)
since patients were observed until they developed a first recur-
rence, not until progression. Nevertheless, progression occurred
significantly more often after MM treatment than after KLH treat-
ment. Univariate Cox regression analysis for PFS showed no statis-
tically significant difference between KLH and MM (HR, 0.38; 95%
CI, 0.14 to 1.04; P  .059). When correcting for confounding
factors by including more pT1 tumors in the MM group, the
statistical significance was even less obvious (adjusted HR, 0.43;
95% CI, 0.15 to 1.17; P  .099). This suggests that the larger
number of patients with pT1 tumors in the MM group might have
introduced a bias. Because our results on progression are conflict-
ing and paradoxical compared with the results of other studies,
further research should focus on clarifying this.
There is little literature on progression after KLH. Jurincic et
al10 found progression in three patients treated with MM versus in
one patient treated with KLH. However, progression was defined
as upgrading. No progression was found after KLH treatment in
patients with CIS, but mean follow-up was only 23.5 months.11
Ka¨lble et al11 found an increase in grade or stage in two patients
(11.8%) after KLH treatment versus no progression after BCG. As
in other studies,6,10,11,13,15,16 we found generally mild AEs af-
ter KLH instillations.
In this study, the MM schedule was instillations once per week for
4 weeks and then once per month for 7 months, which was the
schedule commonly in use when this trial was conducted. Currently,
Table 3. Individual Crude HRs Calculated with Univariate Cox Regression for RFS and PFS
Variable
RFS PFS
HR 95% CI P HR 95% CI P
Treatment (reference group, MM) 2.26 1.74 to 2.94  .001 0.38 0.14 to 1.04 .059
Sex (reference group, male) 0.94 0.68 to 1.31 .720 1.22 0.41 to 3.66 .719
Prior recurrence rate (reference group, primary) 1.43 1.12 to 1.84 .005 0.60 0.23 to 1.57 .297
Tumor stage (reference group, Ta) 0.99 0.73 to 1.35 .967 3.85 1.59 to 9.33 .003
Grade 2 tumor (reference group, grade 1) 1.26 0.96 to 1.66 .097 7.16 0.92 to 55.45 .060
Grade 3 tumor (reference group, grade 1) 0.88 0.57 to 1.36 .562 19.89 2.49 to 159.03 .005
Tumor size (reference group,  15 mm) 0.82 0.62 to 1.08 .152 0.65 0.24 to 1.75 .392
No. of tumors (reference group, single)† 1.94 1.45 to 2.58  .001 1.39 0.53 to 3.61 .505
Abbreviations: HR, hazard ratio; MM, mitomycin; PFS, progression-free survival; RFS, recurrence-free survival.
Prior recurrence rate: primary v recurrent.
†No. of tumors: single v multiple tumors.
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Fig 2. Kaplan-Meier curve for recurrence-free survival. KLH, keyhole limpet
hemocyanin; MM, mitomycin.
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many different schedules are being used for MM, and guidelines do
not recommend any particular schedule.5,17,18
Patients in this study had mainly intermediate or high risk of
recurrences. The current guidelines advise BCG treatment for these
patients,5,18 because randomized controlled trials and meta-analyses
have shown BCG maintenance to be superior to MM in preventing
recurrences.19,20 However, literature on superiority of BCG over MM
for progression is less clear, as shown by Ma¨lmstrom et al.20 This
suggests that KLH is also inferior to BCG. Only Ka¨lble et al11 com-
pared BCG with KLH, and they indeed found that KLH is inferior
to BCG.
Our results are contradictory on the need for preimmuniza-
tion: a positive skin test appeared to be a prognostic factor for
recurrences, but a negative DTH response was associated with
progression. However, preimmunization was adequate in only
62% of the patients.
The exact mechanism behind KLH is not known. The most
likely hypothesis is that KLH enhances the cellular immune
system,21-25 which is the rationale behind preimmunization. Sev-
eral studies reported on the need for preimmunization: Swerdlow
et al26 found fewer tumors in mice preimmunized with KLH than
in mice without preimmunization. However, the effect also de-
pended on the intravesical KLH dose. Lamm et al27 found signifi-
cantly reduced tumor incidence and tumor volume (P .001) and
significantly increased survival (P  .001) of mice after immuni-
zation before tumor transplantation compared with immuniza-
tion after tumor transplantation. Jurincic-Winkler et al25 found a
relationship between positive skin test and fewer recurrences in
only nine patients with primary NMIBC treated with intravesi-
cal KLH. As suggested by Oyelaran et al,28 differences in clinical
responses with KLH may be due to differences in antibody
profiles, which vary considerably from person to person. In all, the
immunology behind KLH has not been clarified and needs fur-
ther testing.
KLH is registered for prevention of bladder cancer after
TURBT and after failure of established therapies. In a subgroup
analysis with these patients (n  81), RFS was not significantly
different between the KLH and MM arms. However, these results
should be interpreted with care because subgroup analyses are
prone to selection bias and, because of the small sample size, they
are often underpowered. Therefore, no firm conclusions can be
drawn from these subgroup analyses.
In daily urologic practice, NMIBC is sometimes coagulated in-
stead of resected, but this means a lack of histologic confirmation.
Therefore, additional analyses were done in which coagulated lesions,
lack of biopsies, or lack of any resection were considered to be a
protocol violation. Then, 210 patients developed a recurrence, with
significantly more recurrences and significantly shorter RFS for KLH
patients (both P .001).
Sometimes in daily urologic practice, a recurrence is seen at
cystoscopy but is not immediately resected. When considering the
date at which the recurrence was first seen to be the date of recurrence,
RFS was significantly shorter after KLH treatment than after MM
treatment (P .001). When considering all lesions, whether patho-
logically confirmed, coagulated, or not resected at all, to be a recur-
rence, RFS was once more significantly shorter for patients treated
with KLH (P .001).
In conclusion, this prospective, randomized phase III trial shows
that KLH had a safety profile different from that of MM. Patients with
a positive skin test as a result of preimmunization with intracutaneous
KLH had significantly more recurrences. KLH was inferior to MM in
preventing NMIBC recurrences. KLH tended to prevent progression
more effectively than MM, but when correcting for the higher number
of patients with pT1 tumors, this could not be shown. More research is
needed to clarify the immunologic effects of KLH and the effects of
KLH on progression.
Table 4. Adjusted HRs Calculated With Multivariate Cox Regression for RFS and PFS
Variable
RFS PFS
HR 95% CI P HR 95% CI P
Treatment (reference group, MM 2.32 1.79 to 3.02  .001 0.43 0.15 to 1.17 .099
Prior recurrence rate (reference group, primary) 1.36 1.06 to 1.75 .015 N/A N/A
Tumor stage (reference group, Ta) N/A N/A 2.13 0.82 to 5.56 .121
Grade 2 tumor (reference group, grade 1) N/A N/A 5.66 0.71 to 44.90 .101
Grade 3 tumor (reference group, grade 1) N/A N/A 11.76 1.34 to 103.53 .026
No. of tumors (reference group, single)† 1.88 1.41 to 2.51  .001 N/A N/A
Abbreviations: HR, hazard ratio; MM, mitomycin; N/A, not applicable; PFS, progression-free survival; RFS, recurrence-free survival.
Prior recurrence rate: primary v recurrent.
†No. of tumors: single v multiple tumors.
Table 5. Relationship Between DTH Response and Clinical Outcome
Response
DTH Response
Positive Negative Unknown
TotalNo. % No. % No. %
Recurrence
Yes 109 66 51 53 3 60 163
No 56 34 46 47 2 40 104
Total 165 100 97 100 5 100 267
Progression
Yes 1 1 4 4 0 0 5
No 164 99 93 96 5 100 262
Total 165 100 97 100 5 100 267
NOTE. A positive delayed-type hypersensitivity (DTH) is associated with a
higher chance of recurrence (two-sided Pearson 2 test P  .031). A negative
DTH is associated with a higher chance of progression (two-sided Pearson 2
test P  .044).
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